Hereditary muscular dystrophies and the heart

Neuromuscular Disorders

Volumn 20, Issue 8, 2010, Pages 479-492

  Hermans, M C E ^a   Pinto, Y M ^b   Merkies, I S J ^a,c   de Die Smulders, C E M ^a   Crijns, H J G M ^a   Faber, C G ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Department of Orthopaedic Surgery   (Netherlands)

Author keywords

Arrhythmia; Cardiomyopathy; Muscular dystrophy; Sudden death; Treatment

Indexed keywords

ALPHA SARCOGLYCAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA SARCOGLYCAN; CORTICOSTEROID; DELTA SARCOGLYCAN; DESMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYSTROPHIN; EMERIN; FUKUTIN RELATED PROTEIN; GAMMA SARCOGLYCAN; LAMIN A; LAMIN C; MYOSIN HEAVY CHAIN BETA; MYOTONIC DYSTROPHY PROTEIN KINASE;

AUTOSOMAL DOMINANT DISORDER; BARTH SYNDROME; BECKER MUSCULAR DYSTROPHY; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; DUCHENNE MUSCULAR DYSTROPHY; ECG ABNORMALITY; EMERY DREIFUSS MUSCULAR DYSTROPHY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE MUTATION; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LIMB GIRDLE MUSCULAR DYSTROPHY; MCLEOD SYNDROME; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOTONIC DYSTROPHY; ONSET AGE; PHYSICAL DISABILITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; REVIEW; SUDDEN DEATH; X CHROMOSOME LINKED DISORDER;

CARDIOMYOPATHY, DILATED; GENETIC DISEASES, X-LINKED; HEART DISEASES; HETEROZYGOTE; HUMANS; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MUSCULAR DYSTROPHY, DUCHENNE; MUSCULAR DYSTROPHY, EMERY-DREIFUSS; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; MYOCARDIUM; MYOFIBRILS; MYOTONIC DYSTROPHY;

EID: 77955267033     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2010.04.008     Document Type: Review

References (170)

1. OMIM® Online Mendelian Inheritance in Man. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD).
2. Emery A.E. Population frequencies of inherited neuromuscular diseases - a world survey. Neuromuscul Disord 1991, 1:19-29.
3. Eagle M., Baudouin S.V., Chandler C., Giddings D.R., Bullock R., Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002, 12:926-929.
4. Bushby K.M., Thambyayah M., Gardner-Medwin D. Prevalence and incidence of Becker muscular dystrophy. Lancet 1991, 337:1022-1024.
5. Emery A.E., Skinner R. Clinical studies in benign (Becker type) X-linked muscular dystrophy. Clin Genet 1976, 10:189-201.
6. Bradley W.G., Jones M.Z., Mussini J.M., Fawcett P.R. Becker-type muscular dystrophy. Muscle Nerve 1978, 1:111-132.
7. Bushby K.M., Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. J Neurol 1993, 240:98-104.
8. Hoogerwaard E.M., de Voogt W.G., Wilde A.A., van der Wouw P.A., Bakker E., van Ommen G.J., et al. Evolution of cardiac abnormalities in Becker muscular dystrophy over a 13-year period. J Neurol 1997, 244:657-663.
9. Towbin J.A., Hejtmancik J.F., Brink P., Gelb B., Zhu X.M., Chamberlain J.S., et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993, 87:1854-1865.
10. Monaco A.P., Bertelson C.J., Liechti-Gallati S., Moser H., Kunkel L.M. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988, 2:90-95.
11. Petrof B.J., Shrager J.B., Stedman H.H., Kelly A.M., Sweeney H.L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 1993, 90:3710-3714.
12. Wallace G.Q., McNally E.M. Mechanisms of Muscle Degeneration, Regeneration, and Repair in the Muscular Dystrophies. Annu Rev Physiol 2009, 71:37-57.
13. Perloff J.K. Cardiac rhythm and conduction in Duchenne's muscular dystrophy: a prospective study of 20 patients. J Am Coll Cardiol 1984, 3:1263-1268.
14. Ishikawa K. Cardiac involvement in progressive muscular dystrophy of the Duchenne type. Jpn Heart J 1997, 38:163-180.
15. Sanyal S.K., Johnson W.W. Cardiac conduction abnormalities in children with Duchenne's progressive muscular dystrophy: electrocardiographic features and morphologic correlates. Circulation 1982, 66:853-863.
16. Nigro G., Comi L.I., Politano L., Bain R.J. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990, 26:271-277.
17. Yanagisawa A., Miyagawa M., Yotsukura M., Tsuya T., Shirato C., Ishihara T., et al. The prevalence and prognostic significance of arrhythmias in Duchenne type muscular dystrophy. Am Heart J 1992, 124:1244-1250.
18. Chenard A.A., Becane H.M., Tertrain F., de Kermadec J.M., Weiss Y.A. Ventricular arrhythmia in Duchenne muscular dystrophy: prevalence, significance and prognosis. Neuromuscul Disord 1993, 3:201-206.
19. American Academy of Pediatrics Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics 2005, 116:1569-1573.
20. Corrado G., Lissoni A., Beretta S., Terenghi L., Tadeo G., Foglia-Manzillo G., et al. Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. Am J Cardiol 2002, 89:838-841.
21. Duboc D., Meune C., Lerebours G., Devaux J.Y., Vaksmann G., Becane H.M. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005, 45:855-857.
22. Duboc D., Meune C., Pierre B., Wahbi K., Eymard B., Toutain A., et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007, 154:596-602.
23. Cohn R.D., van Erp C., Habashi J.P., Soleimani A.A., Klein E.C., Lisi M.T., et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007, 13:204-210.
24. Chamberlain J.S. ACE inhibitor bulks up muscle. Nat Med 2007, 13:125-126.
25. Steare S.E., Dubowitz V., Benatar A. Subclinical cardiomyopathy in Becker muscular dystrophy. Br Heart J 1992, 68:304-308.
26. Nigro G., Comi L.I., Politano L., Limongelli F.M., Nigro V., De Rimini M.L., et al. Evaluation of the cardiomyopathy in Becker muscular dystrophy. Muscle Nerve 1995, 18:283-291.
27. Saito M., Kawai H., Akaike M., Adachi K., Nishida Y., Saito S. Cardiac dysfunction with Becker muscular dystrophy. Am Heart J 1996, 132:642-647.
28. Melacini P., Fanin M., Danieli G.A., Villanova C., Martinello F., Miorin M., et al. Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. Circulation 1996, 94:3168-3175.
29. Bushby K., Muntoni F., Bourke J.P. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord 2003, 13:166-172.
30. Connuck D.M., Sleeper L.A., Colan S.D., Cox G.F., Towbin J.A., Lowe A.M., et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 2008, 155:998-1005.
31. Jefferies J.L., Eidem B.W., Belmont J.W., Craigen W.J., Ware S.M., Fernbach S.D., et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005, 112:2799-2804.
32. Kaspar R.W., Allen H.D., Ray W.C., Alvarez C.E., Kissel J.T., Pestronk A., et al. Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in Becker muscular dystrophy. Circ Cardiovasc Genet 2009, 2:544-551.
33. Politano L., Nigro V., Nigro G., Petretta V.R., Passamano L., Papparella S., et al. Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. JAMA 1996, 275:1335-1338.
34. Nolan M.A., Jones O.D., Pedersen R.L., Johnston H.M. Cardiac assessment in childhood carriers of Duchenne and Becker muscular dystrophies. Neuromuscul Disord 2003, 13:129-132.
35. Hoogerwaard E.M., Bakker E., Ippel P.F., Oosterwijk J.C., Majoor-Krakauer D.F., Leschot N.J., et al. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet 1999, 353:2116-2119.
36. Hoogerwaard E.M., van der Wouw P.A., Wilde A.A., Bakker E., Ippel P.F., Oosterwijk J.C., et al. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 1999, 9:347-351.
37. Grain L., Cortina-Borja M., Forfar C., Hilton-Jones D., Hopkin J., Burch M. Cardiac abnormalities and skeletal muscle weakness in carriers of Duchenne and Becker muscular dystrophies and controls. Neuromuscul Disord 2001, 11:186-191.
38. Melacini P., Fanin M., Angelini A., Pegoraro E., Livi U., Danieli G.A., et al. Cardiac transplantation in a Duchenne muscular dystrophy carrier. Neuromuscul Disord 1998, 8:585-590.
39. Davies J.E., Winokur T.S., Aaron M.F., Benza R.L., Foley B.A., Holman W.L. Cardiomyopathy in a carrier of Duchenne's muscular dystrophy. J Heart Lung Transplant 2001, 20:781-784.
40. Holloway S.M., Wilcox D.E., Wilcox A., Dean J.C., Berg J.N., Goudie D.R., et al. Life expectancy and death from cardiomyopathy amongst carriers of Duchenne and Becker muscular dystrophy in Scotland. Heart 2008, 94:633-636.
41. Berko B.A., Swift M. X-linked dilated cardiomyopathy. N Engl J Med 1987, 316:1186-1191.
42. Ferlini A., Sewry C., Melis M.A., Mateddu A., Muntoni F. X-linked dilated cardiomyopathy and the dystrophin gene. Neuromuscul Disord 1999, 9:339-346.
43. Bione S., Maestrini E., Rivella S., Mancini M., Regis S., Romeo G., et al. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet 1994, 8:323-327.
44. Manilal S., Nguyen T.M., Sewry C.A., Morris G.E. The Emery-Dreifuss muscular dystrophy protein, emerin, is a nuclear membrane protein. Hum Mol Genet 1996, 5:801-808.
45. Nagano A., Koga R., Ogawa M., Kurano Y., Kawada J., Okada R., et al. Emerin deficiency at the nuclear membrane in patients with Emery-Dreifuss muscular dystrophy. Nat Genet 1996, 12:254-259.
46. Manilal S., Recan D., Sewry C.A., Hoeltzenbein M., Llense S., Leturcq F., et al. Mutations in Emery-Dreifuss muscular dystrophy and their effects on emerin protein expression. Hum Mol Genet 1998, 7:855-864.
47. Bonne G., Di Barletta M.R., Varnous S., Becane H.M., Hammouda E.H., Merlini L., et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999, 21:285-288.
48. Raffaele Di Barletta M., Ricci E., Galluzzi G., Tonali P., Mora M., Morandi L., et al. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2000, 66:1407-1412.
49. Benedetti S., Merlini L. Laminopathies: from the heart of the cell to the clinics. Curr Opin Neurol 2004, 17:553-560.
50. Bonne G., Mercuri E., Muchir A., Urtizberea A., Becane H.M., Recan D., et al. Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. Ann Neurol 2000, 48:170-180.
51. Manilal S., Sewry C.A., Pereboev A., Man N., Gobbi P., Hawkes S., et al. Distribution of emerin and lamins in the heart and implications for Emery-Dreifuss muscular dystrophy. Hum Mol Genet 1999, 8:353-359.
52. Bonne G, Leturcq F, Récan-Budiartha D, Ben Yaou R. (Updated 21 November 2007). Emery-Dreifuss muscular dystrophy. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. Available at [accessed 14 September 2009]; 1997-2009. http://www.genetests.org.
53. Zhang Q., Bethmann C., Worth N.F., Davies J.D., Wasner C., Feuer A., et al. Nesprin-1 and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. Hum Mol Genet 2007, 16:2816-2833.
54. Tsuchiya Y., Hase A., Ogawa M., Yorifuji H., Arahata K. Distinct regions specify the nuclear membrane targeting of emerin, the responsible protein for Emery-Dreifuss muscular dystrophy. Eur J Biochem 1999, 259:859-865.
55. Lammerding J., Hsiao J., Schulze P.C., Kozlov S., Stewart C.L., Lee R.T. Abnormal nuclear shape and impaired mechanotransduction in emerin-deficient cells. J Cell Biol 2005, 170:781-791.
56. Bakay M., Wang Z., Melcon G., Schiltz L., Xuan J., Zhao P., et al. Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain 2006, 129:996-1013.
57. Waters D.D., Nutter D.O., Hopkins L.C., Dorney E.R. Cardiac features of an unusual X-linked humeroperoneal neuromuscular disease. N Engl J Med 1975, 293:1017-1022.
58. Voit T., Krogmann O., Lenard H.G., Neuen-Jacob E., Wechsler W., Goebel H.H., et al. Emery-Dreifuss muscular dystrophy: disease spectrum and differential diagnosis. Neuropediatrics 1988, 19:62-71.
59. Bialer M.G., McDaniel N.L., Kelly T.E. Progression of cardiac disease in Emery-Dreifuss muscular dystrophy. Clin Cardiol 1991, 14:411-416.
60. Fishbein M.C., Siegel R.J., Thompson C.E., Hopkins L.C. Sudden death of a carrier of X-linked Emery-Dreifuss muscular dystrophy. Ann Intern Med 1993, 119:900-905.
61. Merlini L., Granata C., Dominici P., Bonfiglioli S. Emery-Dreifuss muscular dystrophy: report of five cases in a family and review of the literature. Muscle Nerve 1986, 9:481-485.
62. Funakoshi M., Tsuchiya Y., Arahata K. Emerin and cardiomyopathy in Emery-Dreifuss muscular dystrophy. Neuromuscul Disord 1999, 9:108-114.
63. Boriani G., Gallina M., Merlini L., Bonne G., Toniolo D., Amati S., et al. Clinical relevance of atrial fibrillation/flutter, stroke, pacemaker implant, and heart failure in Emery-Dreifuss muscular dystrophy: a long-term longitudinal study. Stroke 2003, 34:901-908.
64. Sakata K., Shimizu M., Ino H., Yamaguchi M., Terai H., Fujino N., et al. High incidence of sudden cardiac death with conduction disturbances and atrial cardiomyopathy caused by a nonsense mutation in the STA gene. Circulation 2005, 111:3352-3358.
65. van der Kooi A.J., Ledderhof T.M., de Voogt W.G., Res C.J., Bouwsma G., Troost D., et al. A newly recognized autosomal dominant limb girdle muscular dystrophy with cardiac involvement. Ann Neurol 1996, 39:636-642.
66. Fatkin D., MacRae C., Sasaki T., Wolff M.R., Porcu M., Frenneaux M., et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999, 341:1715-1724.
67. Becane H.M., Bonne G., Varnous S., Muchir A., Ortega V., Hammouda E.H., et al. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing Clin Electrophysiol 2000, 23:1661-1666.
68. Brodsky G.L., Muntoni F., Miocic S., Sinagra G., Sewry C., Mestroni L. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation 2000, 101:473-476.
69. van Berlo J.H., de Voogt W.G., van der Kooi A.J., van Tintelen J.P., Bonne G., Yaou R.B., et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death?. J Mol Med 2005, 83:79-83.
70. Meune C., Van Berlo J.H., Anselme F., Bonne G., Pinto Y.M., Duboc D. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med 2006, 354:209-210.
71. Pasotti M., Klersy C., Pilotto A., Marziliano N., Rapezzi C., Serio A., et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol 2008, 52:1250-1260.
72. Bushby K. The limb-girdle muscular dystrophies. Diagnostic criteria for neuromuscular disorders 1997, 17-22. Royal Society of Medicine Press, London. A.E. Emery (Ed.).
73. van der Kooi A.J., Barth P.G., Busch H.F., de Haan R., Ginjaar H.B., van Essen A.J., et al. The clinical spectrum of limb girdle muscular dystrophy. A survey in The Netherlands. Brain 1996, 119(Pt 5):1471-1480.
74. Laval S.H., Bushby K.M. Limb-girdle muscular dystrophies - from genetics to molecular pathology. Neuropathol Appl Neurobiol 2004, 30:91-105.
75. Minetti C., Sotgia F., Bruno C., Scartezzini P., Broda P., Bado M., et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 1998, 18:365-368.
76. Hauser M.A., Conde C.B., Kowaljow V., Zeppa G., Taratuto A.L., Torian U.M., et al. Myotilin Mutation found in second pedigree with LGMD1A. Am J Hum Genet 2002, 71:1428-1432.
77. Messina D.N., Speer M.C., Pericak-Vance M.A., McNally E.M. Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. Am J Hum Genet 1997, 61:909-917.
78. Crosbie R.H., Lim L.E., Moore S.A., Hirano M., Hays A.P., Maybaum S.W., et al. Molecular and genetic characterization of sarcospan: insights into sarcoglycan-sarcospan interactions. Hum Mol Genet 2000, 9:2019-2027.
79. Holt K.H., Campbell K.P. Assembly of the sarcoglycan complex. Insights for muscular dystrophy. J Biol Chem 1998, 273:34667-34670.
80. Fanin M., Duggan D.J., Mostacciuolo M.L., Martinello F., Freda M.P., Soraru G., et al. Genetic epidemiology of muscular dystrophies resulting from sarcoglycan gene mutations. J Med Genet 1997, 34:973-977.
81. Duggan D.J., Manchester D., Stears K.P., Mathews D.J., Hart C., Hoffman E.P. Mutations in the delta-sarcoglycan gene are a rare cause of autosomal recessive limb-girdle muscular dystrophy (LGMD2). Neurogenetics 1997, 1:49-58.
82. Vainzof M., Passos-Bueno M.R., Pavanello R.C., Marie S.K., Oliveira A.S., Zatz M. Sarcoglycanopathies are responsible for 68% of severe autosomal recessive limb-girdle muscular dystrophy in the Brazilian population. J Neurol Sci 1999, 164:44-49.
83. Eymard B., Romero N.B., Leturcq F., Piccolo F., Carrie A., Jeanpierre M., et al. Primary adhalinopathy (alpha-sarcoglycanopathy): clinical, pathologic, and genetic correlation in 20 patients with autosomal recessive muscular dystrophy. Neurology 1997, 48:1227-1234.
84. Barresi R., Confalonieri V., Lanfossi M., Di Blasi C., Torchiana E., Mantegazza R., et al. Concomitant deficiency of beta- and gamma-sarcoglycans in 20 alpha-sarcoglycan (adhalin)-deficient patients: immunohistochemical analysis and clinical aspects. Acta Neuropathol 1997, 94:28-35.
85. Angelini C., Fanin M., Freda M.P., Duggan D.J., Siciliano G., Hoffman E.P. The clinical spectrum of sarcoglycanopathies. Neurology 1999, 52:176-179.
86. Melacini P., Fanin M., Duggan D.J., Freda M.P., Berardinelli A., Danieli G.A., et al. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve 1999, 22:473-479.
87. Politano L., Nigro V., Passamano L., Petretta V., Comi L.I., Papparella S., et al. Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromuscul Disord 2001, 11:178-185.
88. Barresi R., Di Blasi C., Negri T., Brugnoni R., Vitali A., Felisari G., et al. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations. J Med Genet 2000, 37:102-107.
89. Fanin M., Melacini P., Boito C., Pegoraro E., Angelini C. LGMD2E patients risk developing dilated cardiomyopathy. Neuromuscul Disord 2003, 13:303-309.
90. Brockington M., Yuva Y., Prandini P., Brown S.C., Torelli S., Benson M.A., et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet 2001, 10:2851-2859.
91. Beltran-Valero de Bernabe D., Voit T., Longman C., Steinbrecher A., Straub V., Yuva Y., et al. J Med Genet 2004, 41:e61.
92. Muntoni F., Torelli S., Brockington M. Muscular dystrophies due to glycosylation defects. Neurotherapeutics 2008, 5:627-632.
93. Mercuri E., Brockington M., Straub V., Quijano-Roy S., Yuva Y., Herrmann R., et al. Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Ann Neurol 2003, 53:537-542.
94. Poppe M., Bourke J., Eagle M., Frosk P., Wrogemann K., Greenberg C., et al. Cardiac and respiratory failure in limb-girdle muscular dystrophy 2I. Ann Neurol 2004, 56:738-741.
95. Boito C.A., Melacini P., Vianello A., Prandini P., Gavassini B.F., Bagattin A., et al. Clinical and molecular characterization of patients with limb-girdle muscular dystrophy type 2I. Arch Neurol 2005, 62:1894-1899.
96. Sveen M.L., Thune J.J., Kober L., Vissing J. Cardiac involvement in patients with limb-girdle muscular dystrophy type 2 and Becker muscular dystrophy. Arch Neurol 2008, 65:1196-1201.
97. Wahbi K., Meune C., Hamouda el H., Stojkovic T., Laforet P., Becane H.M., et al. Cardiac assessment of limb-girdle muscular dystrophy 2I patients: an echography, Holter ECG and magnetic resonance imaging study. Neuromuscul Disord 2008, 18:650-655.
98. Beckmann J.S., Brown R.H., Muntoni F., Urtizberea A., Bonnemann C., Bushby K.M. 66th/67th ENMC sponsored international workshop: The limb-girdle muscular dystrophies, 26-28 March 1999, Naarden, The Netherlands. Neuromuscul Disord 1999, 9:436-445.
99. Fayssoil A. Cardiac diseases in sarcoglycanopathies. Int J Cardiol 2009.
100. Harper P.S. Myotonic dystrophy 2001, Saunders, London.
101. Höweler C.J., Busch H.F., Geraedts J.P., Niermeijer M.F., Staal A. Anticipation in myotonic dystrophy: fact or fiction?. Brain 1989, 112:779-797.
102. Harley H.G., Rundle S.A., MacMillan J.C., Myring J., Brook J.D., Crow S., et al. Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. Am J Hum Genet 1993, 52:1164-1174.
103. Mathieu J., Allard P., Potvin L., Prevost C., Begin P. A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology 1999, 52:1658-1662.
104. de Die-Smulders C.E., Höweler C.J., Thijs C., Mirandolle J.F., Anten H.B., Smeets H.J., et al. Age and causes of death in adult-onset myotonic dystrophy. Brain 1998, 121:1557-1563.
105. Groh W.J., Groh M.R., Saha C., Kincaid J.C., Simmons Z., Ciafaloni E., et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008, 358:2688-2697.
106. Brook J.D., McCurrach M.E., Harley H.G., Buckler A.J., Church D., Aburatani H., et al. Cell 1992, 69:385.
107. Berul C.I., Maguire C.T., Gehrmann J., Reddy S. Progressive atrioventricular conduction block in a mouse myotonic dystrophy model. J Interv Card Electrophysiol 2000, 4:351-358.
108. Klesert T.R., Otten A.D., Bird T.D., Tapscott S.J. Trinucleotide repeat expansion at the myotonic dystrophy locus reduces expression of DMAHP. Nat Genet 1997, 16:402-406.
109. Ranum L.P., Day J.W. Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet 2004, 74:793-804.
110. Bigot A., Klein A.F., Gasnier E., Jacquemin V., Ravassard P., Butler-Browne G., et al. Large CTG repeats trigger p16-dependent premature senescence in myotonic dystrophy type 1 muscle precursor cells. Am J Pathol 2009, 174:1435-1442.
111. Bassez G., Lazarus A., Desguerre I., Varin J., Laforet P., Becane H.M., et al. Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1. Neurology 2004, 63:1939-1941.
112. Phillips M.F., Harper P.S. Cardiac disease in myotonic dystrophy. Cardiovasc Res 1997, 33:13-22.
113. Hawley R.J., Milner M.R., Gottdiener J.S., Cohen A. Myotonic heart disease: a clinical follow-up. Neurology 1991, 41:259-262.
114. Fragola P.V., Luzi M., Calo L., Antonini G., Borzi M., Frongillo D., et al. Cardiac involvement in myotonic dystrophy. Am J Cardiol 1994, 74:1070-1072.
115. Lazarus A., Varin J., Babuty D., Anselme F., Coste J., Duboc D. Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter diagnostic pacemaker study. J Am Coll Cardiol 2002, 40:1645-1652.
116. Lazarus A., Varin J., Ounnoughene Z., Radvanyi H., Junien C., Coste J., et al. Relationships among electrophysiological findings and clinical status, heart function, and extent of DNA mutation in myotonic dystrophy. Circulation 1999, 99:1041-1046.
117. Nguyen H.H., Wolfe J.T., Holmes D.R., Edwards W.D. Pathology of the cardiac conduction system in myotonic dystrophy: a study of 12 cases. J Am Coll Cardiol 1988, 11:662-671.
118. De Ambroggi L., Raisaro A., Marchiano V., Radice S., Meola G. Cardiac involvement in patients with myotonic dystrophy: characteristic features of magnetic resonance imaging. Eur Heart J 1995, 16:1007-1010.
119. Bhakta D., Lowe M.R., Groh W.J. Prevalence of structural cardiac abnormalities in patients with myotonic dystrophy type I. Am Heart J 2004, 147:224-227.
120. Orndahl G., Thulesius O., Enestroem S., Dehlin O. The heart in myotonic disease. Acta Med Scand 1964, 176:479-491.
121. Hermans M.C., Faber C.G., Pinto Y.M. Sudden death in myotonic dystrophy. N Engl J Med 2008, 359:1626-1628. [author reply 1328-29].
122. Bachinski L.L., Udd B., Meola G., Sansone V., Bassez G., Eymard B., et al. Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet 2003, 73:835-848.
123. Day J.W., Ricker K., Jacobsen J.F., Rasmussen L.J., Dick K.A., Kress W., et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003, 60:657-664.
124. Meola G., Moxley R.T. Myotonic dystrophy type 2 and related myotonic disorders. J Neurol 2004, 251:1173-1182.
125. Liquori C.L., Ricker K., Moseley M.L., Jacobsen J.F., Kress W., Naylor S.L., et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001, 293:864-867.
126. Botta A., Vallo L., Rinaldi F., Bonifazi E., Amati F., Biancolella M., et al. Gene expression analysis in myotonic dystrophy: indications for a common molecular pathogenic pathway in DM1 and DM2. Gene Expr 2007, 13:339-351.
127. Wahbi K., Meune C., Becane H.M., Laforet P., Bassez G., Lazarus A., et al. Left ventricular dysfunction and cardiac arrhythmias are frequent in type 2 myotonic dystrophy: A case control study. Neuromuscul Disord 2009, 19:468-472.
128. von zur Muhlen F., Klass C., Kreuzer H., Mall G., Giese A., Reimers C.D. Cardiac involvement in proximal myotonic myopathy. Heart 1998, 79:619-621.
129. Schoser B.G., Ricker K., Schneider-Gold C., Hengstenberg C., Durre J., Bultmann B., et al. Sudden cardiac death in myotonic dystrophy type 2. Neurology 2004, 63:2402-2404.
130. Schenk S., Loscher S., Mickley F., Hartmann A. Female patient with proximal myotonic myopathy and ventricular tachycardia. Z Kardiol 2005, 94:754-760.
131. Udd B., Meola G., Krahe R., Thornton C., Ranum L.P., Bassez G., et al. 140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord 2006, 16:403-413.
132. Finsterer J. Myotonic dystrophy type 2. Eur J Neurol 2002, 9:441-447.
133. Mostacciuolo M.L., Miorin M., Martinello F., Angelini C., Perini P., Trevisan C.P. Genetic epidemiology of congenital muscular dystrophy in a sample from north-east Italy. Hum Genet 1996, 97:277-279.
134. Allamand V., Guicheney P. Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, LAMA2 gene coding for alpha2 chain of laminin). Eur J Hum Genet 2002, 10:91-94.
135. Toda T., Kobayashi K., Kondo-Iida E., Sasaki J., Nakamura Y. The Fukuyama congenital muscular dystrophy story. Neuromuscul Disord 2000, 10:153-159.
136. Nakanishi T., Sakauchi M., Kaneda Y., Tomimatsu H., Saito K., Nakazawa M., et al. Cardiac involvement in Fukuyama-type congenital muscular dystrophy. Pediatrics 2006, 117:e1187-1192.
137. Brockington M., Blake D.J., Prandini P., Brown S.C., Torelli S., Benson M.A., et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet 2001, 69:1198-1209.
138. Dubowitz V. 41st ENMC International Workshop on Congenital Muscular Dystrophy 8-10 March 1996, Naarden, The Netherlands. Neuromuscul Disord 1996, 6:295-306.
139. Spyrou N., Philpot J., Foale R., Camici P.G., Muntoni F. Evidence of left ventricular dysfunction in children with merosin-deficient congenital muscular dystrophy. Am Heart J 1998, 136:474-476.
140. Fardeau M., Tome F.M., Helbling-Leclerc A., Evangelista T., Ottolini A., Chevallay M., et al. Congenital muscular dystrophy with merosin deficiency: clinical, histopathological, immunocytochemical and genetic analysis. Rev Neurol (Paris) 1996, 152:11-19.
141. Mukoyama M., Hizawa K., Kagawa N., Takahashi K. The life spans, cause of death and pathological findings of Fukuyama type congenital muscular dystrophy-analysis of 24 autopsy cases. Rinsho Shinkeigaku 1993, 33:1154-1156.
142. Lunt P.W. 44th ENMC International Workshop: Facioscapulohumeral Muscular Dystrophy: Molecular Studies 19-21 July 1996, Naarden, The Netherlands. Neuromuscul Disord 1998, 8:126-130.
143. van Deutekom J.C., Wijmenga C., van Tienhoven E.A., Gruter A.M., Hewitt J.E., Padberg G.W., et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2kb tandemly repeated unit. Hum Mol Genet 1993, 2:2037-2042.
144. Stevenson W.G., Perloff J.K., Weiss J.N., Anderson T.L. Facioscapulohumeral muscular dystrophy: evidence for selective, genetic electrophysiologic cardiac involvement. J Am Coll Cardiol 1990, 15:292-299.
145. de Visser M., de Voogt W.G., la Riviere G.V. The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy. Muscle Nerve 1992, 15:591-596.
146. Laforet P., de Toma C., Eymard B., Becane H.M., Jeanpierre M., Fardeau M., et al. Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. Neurology 1998, 51:1454-1456.
147. Trevisan C.P., Pastorello E., Armani M., Angelini C., Nante G., Tomelleri G., et al. Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia. European neurology 2006, 56:1-5.
148. Selcen D. Myofibrillar myopathies. Curr Opin Neurol 2008, 21:585-589.
149. Goldfarb L.G., Dalakas M.C. Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. J Clin Invest 2009, 119:1806-1813.
150. Vicart P., Caron A., Guicheney P., Li Z., Prevost M.C., Faure A., et al. A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. Nat Genet 1998, 20:92-95.
151. Selcen D., Engel A.G. Myofibrillar myopathy caused by novel dominant negative alpha B-crystallin mutations. Ann Neurol 2003, 54:804-810.
152. Selcen D., Muntoni F., Burton B.K., Pegoraro E., Sewry C., Bite A.V., et al. Mutation in BAG3 causes severe dominant childhood muscular dystrophy. Ann Neurol 2009, 65:83-89.
153. Melberg A., Oldfors A., Blomstrom-Lundqvist C., Stalberg E., Carlsson B., Larrson E., et al. Autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy linked to chromosome 10q. Ann Neurol 1999, 46:684-692.
154. Griggs R., Vihola A., Hackman P., Talvinen K., Haravuori H., Faulkner G., et al. Zaspopathy in a large classic late-onset distal myopathy family. Brain 2007, 130:1477-1484.
155. Nishino I., Fu J., Tanji K., Yamada T., Shimojo S., Koori T., et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000, 406:906-910.
156. Murakami N., Goto Y., Itoh M., Katsumi Y., Wada T., Ozawa E., et al. Sarcolemmal indentation in cardiomyopathy with mental retardation and vacuolar myopathy. Neuromuscul Disord 1995, 5:149-155.
157. Sugie K., Yamamoto A., Murayama K., Oh S.J., Takahashi M., Mora M., et al. Clinicopathological features of genetically confirmed Danon disease. Neurology 2002, 58:1773-1778.
158. Spencer C.T., Bryant R.M., Day J., Gonzalez I.L., Colan S.D., Thompson W.R., et al. Cardiac and clinical phenotype in Barth syndrome. Pediatrics 2006, 118:e337-346.
159. Danek A., Rubio J.P., Rampoldi L., Ho M., Dobson-Stone C., Tison F., et al. McLeod neuroacanthocytosis: genotype and phenotype. Ann Neurol 2001, 50:755-764.
160. Windpassinger C., Schoser B., Straub V., Hochmeister S., Noor A., Lohberger B., et al. An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1. Am J Hum Genet 2008, 82:88-99.
161. Schessl J., Taratuto A.L., Sewry C., Battini R., Chin S.S., Maiti B., et al. Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1. Brain 2009, 132:452-464.
162. Carmignac V., Salih M.A., Quijano-Roy S., Marchand S., Al Rayess M.M., Mukhtar M.M., et al. C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. Ann Neurol 2007, 61:340-351.
163. Overeem S., Schelhaas H.J., Blijham P.J., Grootscholten M.I., ter Laak H.J., Timmermans J., et al. Symptomatic distal myopathy with cardiomyopathy due to a MYH7 mutation. Neuromuscul Disord 2007, 17:490-493.
164. Uro-Coste E., Arne-Bes M.C., Pellissier J.F., Richard P., Levade T., Heitz F., et al. Striking phenotypic variability in two familial cases of myosin storage myopathy with a MYH7 Leu1793pro mutation. Neuromuscul Disord 2009, 19:163-166.
165. Manzur A.Y., Kinali M., Muntoni F. Update on the management of Duchenne muscular dystrophy. Arch Dis Child 2008, 93:986-990.
166. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008 [CD003725].
167. Silversides C.K., Webb G.D., Harris V.A., Biggar D.W. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 2003, 91:769-772.
168. Bauer R., Straub V., Blain A., Bushby K., MacGowan G.A. Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail 2009, 11:463-471.
169. Cossu G., Sampaolesi M. New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials. Trends Mol Med 2007, 13:520-526.
170. Wheeler T.M. Myotonic dystrophy: therapeutic strategies for the future. Neurotherapeutics 2008, 5:592-600.